<DOC>
	<DOCNO>NCT00740194</DOCNO>
	<brief_summary>Aromatase inhibition versus estradiol 1 week</brief_summary>
	<brief_title>Reciprocal Influence Sex Steroid Environment Adipocyte Function Men</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Informed consent obtain . Male subject Age 18 40 weight &lt; 120 kg Primary hypogonadism secondary hypogonadism due genetic cause ( Kallman syndrome etc . ) , tumor , infiltrative disease , infection , pituitary apoplexy , trauma , critical illness , chronic systemic illness intentional . Treatment insulin , corticoid , opiate ( daily basis ) , androgen estrogen analog CYP2A6 substrate ( Dexmedetomidine , Ifosfamide , Methoxsalen , Miconazole , Tranylcypromine ) . Impaired renal function define serumcreatine &gt; 1.5 mg/dL Impaired liver function , define ALAT &gt; 2.5 time upper limit normal Clinically significant active cardiovascular disease include history myocardial infarction within past 6 month and/or heart failure ( NYHA class III IV ) discretion investigator Cancer clinically significant disease disorder , investigator 's opinion could interfere result trial Palpable prostate nodule induration , PSA &gt; 3 ng/mL , prostatism , untreated sleep apnee syndrome , erythrocytosis ( hematocrit &gt; 50 % ) hyperviscosity . Known suspected abuse alcohol narcotic Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Physiology</keyword>
	<keyword>male</keyword>
</DOC>